Construction and application of miR-423-5p high-abundance engineered vesicles

By constructing engineered miR-423-5p high-abundance vesicles, the problem of periodontal tissue regeneration in the treatment of periodontitis was solved, and miR-423-5p was delivered efficiently and targetedly, significantly improving the osteogenic capacity of periodontal ligament stem cells.

CN118685365BActive Publication Date: 2024-11-15THE AFFILIATED STOMATOLOGICAL HOSPITAL OF KUNMING MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411166113.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-15
Estimated Expiration
2044-08-23

AI Technical Summary

Technical Problem

Existing treatments for periodontitis are insufficient to achieve structural and functional regeneration of periodontal tissues, and natural small extracellular vesicles have issues with insufficient targeting and safety in clinical applications.

Method used

We constructed engineered vesicles with high miR-423-5p abundance by incubating, centrifuging and purifying miR-423-5p with small extracellular vesicles to prepare engineered vesicles with high miR-423-5p expression levels for targeted delivery to periodontal ligament stem cells.

Benefits of technology

It significantly promotes osteogenic differentiation of periodontal ligament stem cells, improves periodontal tissue regeneration capacity, and miR-423-5p has a long retention time in cells, significantly enhances osteogenic efficacy, and does not affect the expression level of other miRNAs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118685365B_ABST
    Figure CN118685365B_ABST
Patent Text Reader

Abstract

The present invention discloses the construction and application of a high-abundance engineered vesicle of miR‑423‑5p, belonging to the field of biomedical technology. The engineered vesicle constructed by the present invention has the same double-layer membrane structure as natural vesicles, similar particle size and potential value, and similar marker protein expression, and the expression level of miR‑423‑5p in the engineered vesicle constructed by the present invention is 100,000 times that of natural vesicles, and can be internalized by periodontal ligament stem cells, and the miR‑423‑5p carried by itself can be delivered to periodontal ligament stem cells, so that the miR‑423‑5p content in the cell is increased by 338 times, and can remain in the cell for at least 14 d. In addition, the high-abundance engineered vesicle of miR‑423‑5p constructed by the present invention can effectively enhance the osteogenic efficacy of natural vesicles, and significantly promote the osteogenic differentiation of periodontal ligament stem cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to the construction and application of miR-423-5p high-abundance engineered vesicles. Background Art

[0002] Periodontitis is one of the six most common inflammatory diseases in the world. Severe periodontitis not only leads to tooth loss, but is also closely related to a variety of systemic diseases. Currently, clinical treatment mainly relies on plaque removal combined with surgical treatment and supplemented with local or systemic medication. Although it can control inflammation to a certain extent, it is difficult to achieve structural and functional regeneration of periodontal tissues.

[0003] Periodontal ligament stem cells (PDLSCs) are an important type of undifferentiated mesenchymal stem cells in periodontal tissues. Their good proliferation and differentiation potential are of great significance for the formation of periodontal ligament tissues and alveolar bone. However, under long-term chronic inflammatory infiltration, the function of PDLSCs is impaired. The damaged PDLSCs further promote the formation of periodontitis niches, forming a vicious negative regulatory closed loop, which is the main reason for the prolonged periodontitis and progressive destruction of periodontal tissues. Therefore, regulating the regenerative microenvironment, restoring the function of damaged PDLSCs and maintaining their stemness are of great significance for the repair and regeneration of periodontal tissues. Dental follicle stem cells (DFSCs), as the precursor cells of various periodontal tissues, are closely related to PDLSCs.

[0004] Small extracellular vesicles (sEVs) are a new type of cell-free technology that can mediate intercellular communication, have high physical and chemical stability and high biocompatibility. By carrying a variety of biological information structures, they communicate between cells, thereby regulating the body's microenvironment, maintaining the function of local resident host cells, and contributing to the repair and regeneration of a variety of soft and hard tissues in the body. Therefore, they can be used as an excellent carrier for a variety of bioactive substances. Studies have shown that natural sEVs from tumor cells or immune cells can induce anti-tumor activity and have the potential to become cancer vaccines. However, in cancer treatment, there are still some problems with natural sEVs: natural sEVs are easily trapped in non-specific tissues (especially liver and lungs), resulting in insufficient in vivo targeting; the heterogeneity and complexity of natural sEVs will reduce the therapeutic effect and even bring safety issues. Due to the lack of efficient separation, industrial production, and accurate monitoring of drug loading, the use of natural sEVs in clinical practice still has hidden dangers. Therefore, artificially modified engineered sEVs have become a new treatment strategy and are expected to become another option for sEV-based treatment. Summary of the invention

[0005] In order to solve the above-mentioned deficiencies in the prior art, the purpose of the present invention is to provide a construction and application of a high-abundance engineered vesicle of miR-423-5p, so as to solve the problem that the existing treatment methods for periodontitis are difficult to achieve structural and functional regeneration of periodontal tissues.

[0006] The technical solution of the present invention to solve the above technical problems is as follows: provide a miR-423-5p high-abundance engineered vesicle, including small extracellular vesicles and miR-423-5p, the positive chain nucleotide sequence of miR-423-5p is: UGAGGGGCAGAGAGCGAGACUUU, and the reverse chain nucleotide sequence is: AAAGUCUCGCUCUCUGCCCCUCA; the small extracellular vesicle is a small extracellular vesicle secreted by dental follicle stem cells; the miR-423-5p high-abundance engineered vesicle is prepared by the following method:

[0007] (1) Mix miR-423-5p and nucleic acid transfection reagent, and then add small extracellular vesicles for incubation;

[0008] (2) placing the product obtained in step (1) into an adsorption column and centrifuging to obtain miR-423-5p small extracellular vesicles;

[0009] (3) Adding miR-423-5p small extracellular vesicles into an ultrafiltration tube for purification and concentration, retaining the upper liquid, and obtaining.

[0010] Furthermore, in step (1), the incubation temperature is 35-38°C and the incubation time is 0.5-2 h.

[0011] Furthermore, in step (2), the centrifugal speed is 1500-2500 rpm and the centrifugal time is 30-60 s.

[0012] Furthermore, the molecular weight cut-off of the ultrafiltration tube in step (3) is 25-35 kD.

[0013] The present invention also provides an application of a miR-423-5p high-abundance engineered vesicle in the preparation of an anti-inflammatory drug for periodontitis.

[0014] The present invention has the following beneficial effects: The inventors have found that small extracellular vesicles (DFSCs-sEVs) secreted by dental follicle stem cells exhibit certain periodontal tissue regeneration ability by promoting the proliferation, migration and osteogenic differentiation of PDLSCs. High-throughput sequencing and experimental verification found that miR-423-5p, as a highly abundant miRNA in DFSCs-sEVs, has a strong ability to promote osteoblastogenesis. The miR-423-5p high-abundance engineered vesicles constructed by the present invention have the same double-layer membrane structure as natural vesicles, similar particle size and potential values, and similar marker protein expression, and the expression level of miR-423-5p in the engineered vesicles is 100,000 times that of natural vesicles. It can be internalized by periodontal ligament stem cells and deliver the miR-423-5p it carries to periodontal ligament stem cells, causing the miR-423-5p content in the cells to increase by 338 times, and can remain in the cells for at least 14 days. In addition, the miR-423-5p high-abundance engineered vesicles constructed by the present invention have high osteogenic efficacy and can significantly promote the osteogenic differentiation of periodontal ligament stem cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 A heat map showing the biological processes and related signaling pathways involved in differentially expressed miR-423-5p;

[0016] Figure 2 Pie chart showing the expression distribution of differentially expressed miR-423-5p in sEVs;

[0017] Figure 3 Schematic diagram of the construction method of engineered vesicles;

[0018] Figure 4 Figure 1 is the identification diagram of engineered vesicles; Figure A is sEVs and sEVs miR-423-5p Figure B shows transmission electron microscopy images of sEVs and sEVs miR-423-5p Figure 2 shows the particle size of sEVs and sEVs. miR-423-5p Western blot results; Figure D shows sEVs and sEVs miR-423-5p Zeta potential of sEVs and sEVs miR-423-5p The expression level of miR-423-5p in

[0019] Figure 5 sEVs miR-423-5p Targeted delivery of miR-423-5p to PDLSCs; Figure A shows sEVs and sEVs miR -423-5p Fluorescence confocal image of targeted delivery of miR-423-5p to PDLSCs; Figure B shows PDLSCs taking up sEVs and sEVs miR-423-5pAfterwards, the expression levels of miR-423-5p, miR-100-5p, miR-125b-5p, miR-26a-5p, and miR-24-3p in PDLSCs;

[0020] Figure 6 sEVs miR-423-5p Comparison results with liposome delivery; Figure A is a fluorescence confocal image of the degradation of miR-423-5p delivered by two methods in PDLSCs; Figure B is the change in the expression of miR-423-5p delivered by two methods in PDLSCs;

[0021] Figure 7 Detection of sEVs for CCK-8 assays miR-423-5p Effects on the proliferation capacity of PDLSCs;

[0022] Figure 8 sEVs miR-423-5p Effects on the osteogenic differentiation ability of periodontal ligament stem cells; Figure A shows PDLSCs after sEVs and sEVs miR-423-5p Alkaline phosphatase staining after intervention culture; Figure B shows PDLSCs after sEVs and sEVs miR-423-5p Alizarin red staining after intervention culture; Figure C shows PDLSCs after sEVs and sEVs miR-423-5p The expression levels of osteogenic related proteins after intervention culture; Figure D shows PDLSCs after sEVs and sEVs miR-423-5p Quantitative analysis of the expression of osteogenic-related proteins after intervention culture; Figure E shows the expression of osteogenic-related proteins of PDLSCs after sEVs and sEVs miR-423-5p Quantitative analysis of the expression of osteogenesis-related genes after intervention culture. DETAILED DESCRIPTION

[0023] The following examples are only used to explain the present invention and are not intended to limit the scope of the present invention. If no specific conditions are specified in the examples, the conditions are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0024] In order to find miRNAs with good osteogenic effect in sEVs, the present invention cultured and collected DFSCs and sEVs from six different people, added appropriate amount of Trizol to lyse cells and vesicles on ice for 20 min, collected the lysed samples in EP tubes, and labeled them as DFSCs-1~DFSCs-6, sEVs-1~sEVs-6, respectively. The labeled samples were subjected to high-throughput sequencing to obtain the gene sequences of these 12 samples. The gene sequences of these 12 samples were compared with the reference genome through the alignment system HISAT2, and then the results were statistically annotated and compared. The effector miRNAs that play a regenerative role in sEVs were found by bioinformatics analysis of the differential miRNAs in DFSCs and sEVs. Based on high-throughput sequencing data and bioinformatics analysis, hsa-miR-423-5p was found to be one of the important osteogenic effector miRNAs of sEVs, and it was named miR-423-5p. The heat map shows the biological processes and related signaling pathways involved in differentially expressed miR-423-5p, including TGF-β, Hippo, and MAPK signaling pathways related to cell growth and differentiation (see Figure 1, where the labels on the right are from top to bottom: hsa-miR-409-3p|Tarbase, hsa-miR-100-5p|Tarbase, hsa-miR-143-3p|Tarbase, hsa-miR-1246|Tarbase, hsa-miR-423-3p|Tarbase, hsa-miR-199a-3p|Tarbase, hsa-miR-423-5p|Tarbase, hsa-miR-125b-5p|Tarbase, hsa-miR-222-3p|Tarbase, hsa-miR-221-3p|Tarbase se, hsa-miR-320a|Tarbase, hsa-miR-148a-3p|Tarbase, hsa-let-7a-5p|Tarbase, hsa-let-7f-5p|Tarbase, hsa-let-7i-5p|Tarbase, hsa-let-7b-5p|Tarbase, hsa-miR-92a-3p|Tarbase, hsa-miR-21-5p|Tarbase, hsa-miR-26a-5p|Tarbase, hsa-miR-24-3p|Tarbase; the labels below are from left to right: Fatty acid metabolism、Fatty acid biosynthesis、Steroid biosynthesis、Prion diseases、Huntington's disease、ECM-receptor interaction、Glycosaminoglycan biosynthesis-keratan sulfate、Other types of O-glycan biosynthesis、Viralcarcinogenesis、p53 signaling pathway、Oocytemeiosis、Glioma、Lysine degradation、Proteoglycans in cancer、Cell cycle、Bladder cancer、Hippo signalingpathwayHippo(signaling pathway)、Arrhythmogenic rightventricular cardiomyopathy(ARVC)、Protein processing inendoplasmic reticulum(protein processing in endoplasmic reticulum)、RNA transport(RNA transport)、Epstein-Barr virus infection(Epstein-Barr virus infection)、Ubiquitin mediated proteolysis(ubiquitin mediated proteolysis)、HTLV-l infection(HTLV-l infection)、Melanoma(melanoma)、Small cell lungcancer(small cell lungcancer)、Hepatitis B(hepatitis B))、Chronic myeloid leukemia(chronic myeloid leukemia)、Colorectal cancer(colorectal cancer)、Shigellosis(shigellosis)、Thyroid cancer(thyroid cancer)、Estrogen signaling pathway(estrogen signaling pathway)、Adherens junction(adherence junction)、Bacterialinvasion of epithelial cells(bacteria invade epithelial cells)、Renal cell carcinoma, Endocytosis, MAPK signaling pathway, Thyroidhormone signaling pathway, Endometrial cancer, Transcriptional misregulation in cancer, Pathways in cancer, Prostate cancer, Signaling pathways regulatingpluripotency of stem cells, TGF-beta signalingpathway, FoxO signaling pathway), pie chart showing the distribution of differentially expressed miR-423-5p in sEVs (see Figure 2 ).

[0025] Example 1

[0026] A miR-423-5p high-abundance engineered vesicle (denoted as sEVs) miR-423-5p ), including small extracellular vesicles and miR-423-5p. The positive strand nucleotide sequence of miR-423-5p is: UGAGGGGCAGAGAGCGAGACUUU, and the reverse strand nucleotide sequence is: AAAGUCUCGCUCUCUGCCCCUCA.

[0027] Construction of sEVs using Exo-Fect™ siRNA / miRNA Transfection Kit (SBI) miR-423-5p , which is constructed as Figure 3 As shown, the following steps are included:

[0028] (1) Take 100 μL transfection buffer, 4 μL transfection reagent, and 1.25 μL miR-423-5p mimic (miR-423-5p mimic, 20 μM), pipette gently, centrifuge briefly to mix, and let stand at room temperature for 15 min;

[0029] (2) Then, add 100 μL of small extracellular vesicles (sEVs) to the product obtained in step (1), blow gently to mix, and incubate at 37 °C for 1 h to prepare a transfection suspension;

[0030] (3) Take out the clean-up column, gently unscrew the nut at the bottom of the column, set it aside for later use, place the column in a 2 mL collection tube, put it in a centrifuge, and centrifuge at 2000 rpm for 30 s to remove the storage solution; then add 500 μL of column buffer, put it in a centrifuge, and centrifuge at 2000 rpm for 30 s to wash the column. Repeat this step once;

[0031] (4) Put the nut removed in step (3) under the column and tighten it to prevent the liquid from flowing out. Pipette 205.25 μL of the transfection suspension in step (2) into the column and incubate at room temperature for 15 min. Then put it in a centrifuge and centrifuge it at 2000 rpm for 30 s to obtain sEVs. miR-423-5p Vesicles;

[0032] (5) The sEVs obtained in step (4) miR-423-5p The vesicles were added to a 30 kD ultrafiltration tube for concentration and purification to eliminate the toxicity of the transfection reagent. The concentrated upper liquid was the purified sEVs. miR-423-5p Vesicle.

[0033] Example 2 sEVs miR-423-5p Identification of vesicles

[0034] (1) Transmission electron microscopy observation of sEVs miR-423-5p Vesicle morphology

[0035] Take 10 μL of sEVs and miR-423-5p The cells were added dropwise to a copper grid to precipitate for 1 min, and then uranyl acetate was added to stain for 30 s-1 min. The floating liquid was removed with filter paper, dried at room temperature, and observed and imaged under a transmission electron microscope at 100 kV. The transmission electron microscopy results showed that sEVs and sEVs miR-423-5p Both have a double-layered saucer-like structure (see Figure 4 (Figure A in the middle).

[0036] (2) sEVs miR-423-5p Detection of vesicle diameter and potential

[0037] The number and size of particles in the sample were determined using the NanoFCM instrument, and the instrument performance was qualified using standard products. PBS was used to dilute sEVs and sEVs miR-423-5p After the vesicles are loaded, sEVs and sEVs can be obtained after the test. miR-423-5p The particle size and concentration of Figure 4 As shown in Figure B, sEVs and sEVs miR-423-5p The particle size peaks of the vesicles were 81.22 nm and 82.93 nm, respectively. In addition, the potential value was detected by Zeta View PMX110 nanoparticle size tracer analyzer (Particle Metrix, Germany). The Zeta potential results showed that sEVs and sEVs miR-423-5p The average potential values ​​of the two were -35.77 mV and -35.24 mV, respectively. The potential values ​​of the two were similar, indicating that the engineering modification did not reduce the structural stability of natural sEVs ( Figure 4 (D in the middle).

[0038] (3) Identification of sEVs by Western blot miR-423-5p Vesicle marker protein

[0039] ①Collection of protein samples: Removal of DFSCs, sEVs and sEVs miR-423-5p After conventional digestion of DFSCs, wash the cells with PBS by centrifugation. After aspirating PBS, add 100 μL of lysis buffer (RIPA:PMSF=100:1) and lyse on ice. Shake or blow the cells and vesicle samples during the process. After 15-20 min, collect the samples in a centrifuge tube and centrifuge them at 12000 rpm for 25 min. The supernatant is the total protein of the sample. Collect the supernatant and measure the protein concentration.

[0040] ②BCA method to determine protein concentration:

[0041] A. Prepare and draw a standard curve: Take a 96-well ELISA plate and add the following reagents according to Table 1:

[0042] Table 1 BCA standard curve

[0043]

[0044] B. Prepare BCA working solution according to the number of samples and mix thoroughly by inverting;

[0045] C. Mix the sample thoroughly and then pipette 2 μL, pipette 18 μL of standard diluent to make up the sample to 20 μL (diluted 10 times), set three replicate wells as repeats;

[0046] D. Add 200 μL of BCA working solution to each sample and standard protein well, incubate at 37°C in the dark for 30 min, then place on a microplate reader, measure and record the absorbance value of each well at 562 nm, and calculate and prepare a standard curve;

[0047] E. Substitute the absorbance value of the measured sample into the standard curve formula to calculate its protein concentration, and adjust the concentration of each sample with lysis buffer.

[0048] ① Protein denaturation: dilute 5× SDS loading buffer to 1×, then add it to the protein sample, vortex and mix well, then denature at 100°C for 5 min. The denatured protein sample can be directly used for subsequent experiments or temporarily stored in a -80°C refrigerator.

[0049] ②SDS-PAGE electrophoresis: Take two clean and undamaged glass plates, one long and one short, and install them on the gel preparation device. This experiment uses the Omni-Easy™ One-Step PAGE Gel Rapid Preparation Kit (10%) as an example. Prepare the separation gel and stacking gel according to Table 2. After fully mixing, inject the separation gel into the glass plate, then slowly inject the stacking gel onto the separation gel, quickly insert the matching loading comb, and let it stand at room temperature for 15 min. After the stacking gel and separation gel are completely solidified, remove the glass plate, rinse the excess colloid on the outside of the glass plate with distilled water, and then fix it in the electrophoresis tank. Add 1× electrophoresis buffer until the glass plate is completely covered, gently pull out the loading comb, load each protein sample at a mass of 15 μg protein / well, and add 4 μL of protein pre-stained marker to the well on the left of the first sample to indicate the position of proteins of each molecular weight. Connect the power supply and perform electrophoresis according to the conditions of stacking gel: 80 V, 20 min, separation gel: 120 V, 50 min. Stop the electrophoresis when bromophenol blue reaches the bottom of the gel.

[0050] Table 2 Formula of Ya enzyme glue making

[0051]

[0052] ① Transfer: After the electrophoresis is completed, remove the glass plate, rinse the residual electrophoresis solution on the plate with distilled water, gently pry open the plate along one corner of the glass plate, cut off the concentrated gel, retain the complete separation gel part of the sample, soak the gel, filter paper and sponge in the pre-cooled transfer solution, cut the appropriate PVDF membrane according to the size of the gel and soak it in the membrane activation solution for 1 min, and then transfer the PVDF membrane to the transfer solution. Install the transfer device in the following order: cathode plate-sponge-3 layers of filter paper-gel-PVDF membrane-3 layers of filter paper-sponge-anode plate. After installation, put it in the electrophoresis tank and pour in the transfer buffer. Transfer the membrane at 20 V constant voltage for 60 min. If the molecular weight of the target protein to be detected is too large or too small, the transfer time should be adjusted accordingly according to the molecular weight of the target protein.

[0053] ② Blocking: After transfer, wash the PVDF membrane with TBST for 1 min to remove the residual transfer solution on the membrane surface, then soak the membrane in blocking solution and block at room temperature for 30 min.

[0054] ③ Primary antibody incubation: The primary antibody dilution ratios were: CD9 (1:2000), CD63 (1:2000), HSP90 (1:1000), TSG101 (1:1000) and Calnexin (1:1000). The membranes were incubated in the corresponding primary antibody solutions according to the target proteins to be detected. After incubation at room temperature on a shaker for 5 min, the membranes were transferred to a 4°C refrigerator for overnight incubation.

[0055] ④ Secondary antibody incubation: Recover the primary antibody solution, wash the membrane three times with TBST with shaking, 10 min each time, soak the membrane in the secondary antibody solution with the following dilution ratios: rabbit antibody (1:5000), mouse antibody (1:5000), incubate at room temperature on a shaker for 90 min, and wash three times with TBST, 15 min each time.

[0056] ⑤ Development: Prepare the developing reaction solution under light-proof conditions, absorb the excess TBST liquid on the PVDF membrane with filter paper, add the developing solution dropwise on the membrane, and develop on the machine.

[0057] Western blot results showed that sEVs and sEVs miR-423-5p All of them positively expressed exosome marker proteins CD9, CD63, TSG101 and HSP90, and negatively expressed endoplasmic reticulum protein Calnexin (see Figure 4 (Figure C).

[0058] (4) miR-423-5p expression level

[0059] ① miRNA extraction: sEVs and sEVs miR-423-5pThe vesicles were added to the cell lysis buffer for lysis, and then allowed to stand at room temperature for 5 min. After adding 200 μL of chloroform, the mixture was shaken vigorously for 15 s, and then allowed to stand at room temperature for 5 min. The mixture was placed in a centrifuge and centrifuged at 12,000 rpm for 15 min at 4 °C. The upper colorless aqueous phase was transferred to a new tube, and anhydrous ethanol 0.43 times the volume of the transfer buffer was added. After mixing, the mixture was transferred to the adsorption column and centrifuged at 12,000 rpm for 30 s. The lower filtrate was retained. Anhydrous ethanol 0.75 times the volume of the filtrate was added, and after mixing, the mixture was transferred to the adsorption column and centrifuged at 12,000 rpm for 30 s. The upper adsorption column was retained. 500 μL of MRD deproteinization solution was added to the adsorption column, and the mixture was allowed to stand at room temperature for 2 min. The mixture was centrifuged at 12,000 rpm for 30 s, and the filtrate was discarded. Subsequently, 500 μL of RW rinse solution was added, and the mixture was allowed to stand at room temperature for 2 min. The mixture was centrifuged at 12,000 rpm for 30 s, discard the filtrate, and repeat this step once; reset the adsorption column in the collection tube, centrifuge at 12000 rpm for 1 min, remove the residual liquid, transfer the adsorption column to a new 1.5 mL RNase-free EP tube, add 20 μL RNase Free ddH2O, let it stand at room temperature for 2 min, centrifuge at 12000 rpm for 2 min, and collect miRNA; after thorough mixing, take 2 μL of sample and use Quawell Q3000 micro-volume UV spectrophotometer to determine the miRNA concentration.

[0060] ② Reverse transcription reaction: Follow the instructions of Mir-X miRNA First-Strand Synthesis Kit. Place the RNase Free 0.2 mL reaction tube on ice and add the reagents in Table 3 to 10 μL.

[0061] Table 3 Reagents and quantities required for mRQ Enzyme reverse transcription reaction

[0062]

[0063] The reaction solution was collected and mixed by instant centrifugation, and then placed in a gradient PCR instrument for reverse transcription reaction. The reaction conditions were: 37 °C for 1 h, 85 °C for 5 min, and 4 °C for termination of the reaction. The reaction solution obtained by transcription was diluted 10 times and can be directly used in PCR experiments or temporarily stored at -80 °C.

[0064] ③ Real-time quantitative PCR: Prepare PCR reaction solution on ice according to Table 4. Add each component in the table to a 96-well plate, centrifuge for 1 min, collect and mix the reaction solution, and TMThe reaction was carried out in the Real-Time PCR System according to the following procedure: 95°C denaturation for 3-5 s, 55°C annealing for 10 s, 72°C extension for 34 s, and 40 cycles. After the reaction was completed, the CT value of each gene was recorded, and the relative expression of the gene was calculated according to the formula x=2-∆∆Ct, where x is the CT value of each target gene in each group. U6 Corrected fold relative to the control group.

[0065] The results are as follows Figure 4 As shown in Figure E, Figure 4 Figure E shows that sEVs miR-423-5p The expression level of miR-423-5p contained in the sEVs was 100,000 times that of sEVs, indicating that sEVs were successfully constructed. miR-423-5p Vesicle.

[0066] Table 4 Reagents and quantities required for TB Green Advantage PCR reaction

[0067]

[0068] Example 3 sEVs miR-423-5p Targeted delivery of miR-423-5p to PDLSCs

[0069] (1) PKH26 was used to label sEVs (red dot-like fluorescence), green fluorescence was used to label miR-423-5p, and CellMask™ Actin Tracking Stains were used to label the PDLSCs cytoskeleton (red flake-like fluorescence). miR -423-5p After being co-cultured with PDLSCs for 24 h, they were all taken up by PDLSCs to the perinuclear and cytoplasmic regions ( Figure 5 Middle A). PDLSCs uptake sEVs miR-423-5p Afterwards, not only were structurally intact sEVs observed around the nucleus miR-423-5p (Orange fluorescence presented by overlapping red and green fluorescence, Figure 5 In Figure A, yellow arrows were used to indicate the presence of sEVs (red fluorescence, Figure 5 In Figure A, red arrows indicate) and miR-423-5p (green fluorescence, Figure 5 (Indicated by the green arrow in Figure A).

[0070] (2) 10 μg / mL of sEVs and sEVs were respectively miR-423-5pAfter co-culture with PDLSCs, miRNA was extracted from the cells after 48 h, and PCR experiments were used to quantitatively detect the expression levels of miR-423-5p and other miRNAs (miR-100-5p, miR-125b-5p, miR-26a-5p, and miR-24-3p) in PDLSCs.

[0071] PCR quantitative analysis showed that after PDLSCs took up sEVs, the expression levels of various miRNAs contained in them, such as miR-423-5p, miR-100-5p, miR-125b-5p, miR-26a-5p, and miR-24-3p, were increased. miR-423-5p After that, the expression level of miR-423-5p contained in it increased significantly, the expression level was 338.38 times of the original, while the expression levels of the other four miRNAs did not change significantly. This result suggests that the engineered vesicles constructed by the method of the present invention can target and accurately deliver miR-423-5p without affecting the expression levels of other miRNAs in the target cells (see Figure 5 (Figure B).

[0072] Example 4 sEVs miR-423-5p Comparison with liposome delivery

[0073] In clarifying sEVs miR-423-5p After being taken up by PDLSCs and targeted delivery of miR-423-5p, the present invention further observed the sEVs by comparing with the commonly used liposome delivery method. miR-423-5p The degradation rate of delivered miR-423-5p in cells was observed under confocal microscopy. After 1 day of co-culture, a large amount of miR-423-5p mimics with green fluorescence were observed in the cytoplasm of PDLSCs in the miR-423-5p mimics group. miR-423-5p A large number of red fluorescent sEVs and green fluorescent miR-423-5p mimics were observed in the cytoplasm and perinuclear area of ​​PDLSCs in the two groups. As the observation time prolonged, the number of fluorescent cells in both groups gradually decreased. At 14 days, no fluorescence was observed in the miR-423-5p mimics group under the microscopic field of view, while sEVs miR-423-5p In the PDLSCs group, a small amount of green fluorescence and a large amount of red fluorescence were still observed around the nucleus and cytoplasm. Figure 6 In addition, in the presence of miR-423-5p mimics or sEVs miR-423-5p Cell miRNA was extracted on days 1, 3, 7 and 14 of intervention culture of PDLSCs, and the expression changes of miR-423-5p in PDLSCs were quantitatively detected by PCR experiments.

[0074] PCR quantitative analysis showed that the miR-423-5p content in PDLSCs of the miR-423-5p mimic group decreased sharply after 3 days, while the miR-423-5p content in sEVs miR-423-5p The miR-423-5p content in PDLSCs of the 1 group decreased slowly from 1 day to 14 days ( Figure 6 Figure B), indicating that sEVs miR-423-5p It protects and slows the release of the encapsulated miR-423-5p.

[0075] Example 5 CCK-8 assay to detect sEVs miR-423-5p Effects on the proliferation capacity of PDLSCs

[0076] P3 generation PDLSCs were seeded in a 96-well plate at a density of 3000 cells / well / 100 μL. After the cells attached to the wall and stretched in morphology, the culture medium was replaced with DMEM / F-12 medium without FBS, and the cells were starved overnight. The next day, except for the day 0 plate, the culture medium of the remaining plates was replaced according to the grouping requirements. The old culture medium of the day 0 plate was discarded, and 90 μL DMEM / F-12 medium and 10 μL CCK-8 solution were added to each well. After incubation at 37 ℃ in the dark for 2 h, the OD value was measured on the machine. In the next 1-7 days, a plate was incubated with CCK-8 solution at the same time every day and the OD value was measured on the machine. The culture medium of the remaining plates was changed every two days according to the grouping and routinely cultured until the plate detection on the 7th day was completed.

[0077] The results are as follows Figure 7 As shown, the results showed that sEVs and sEVs miR-423-5p In the early stage, sEVs had no significant effect on the proliferation level of PDLSCs, but significantly promoted the proliferation of PDLSCs from 3 to 7 days. miR-423-5p The proliferation-promoting ability of sEVs was lower than that of sEVs, but on the 6th and 7th days, sEVs miR-423-5p The proliferation level of the sEVs group gradually approached that of the natural vesicle group, indicating that miR-423-5p The pro-proliferation properties of sEVs were retained.

[0078] Example 6 sEVs miR-423-5p Effects on osteogenic differentiation of periodontal ligament stem cells

[0079] To clarify sEVs miR-423-5p The present invention uses sEVs and sEVs under mineralization induction conditions to influence the osteogenic differentiation potential of PDLSCs. miR-423-5pPDLSCs were cultured and alkaline phosphatase staining was performed 5 days after intervention, the expression levels of osteogenesis-related indicators (ALP, OSX, Runx2, COL1) were detected 7 days after intervention, and alizarin red staining was performed 10 days after intervention. The specific steps are as follows:

[0080] (1) Alkaline phosphatase staining: After 5 days of mineralization induction, the old culture medium was washed with PBS, the cells were fixed, and the alkaline phosphatase staining working solution prepared according to Table 5 was added dropwise to the cells for staining in the dark for 10 min. The staining was terminated with distilled water and the cells were rinsed three times. The alkaline phosphatase staining of each group was observed under an inverted phase contrast microscope under wet conditions and images were taken.

[0081] Table 5 Alkaline phosphatase working solution

[0082]

[0083] Alkaline phosphatase staining results Figure 8 As shown in Figure A, the results show that sEVs and sEVs miR-423-5p All of them can promote the production of alkaline phosphatase in PDLSCs, among which sEVs miR-423-5p The alkaline phosphatase staining of PDLSCs treated with sEVs was significantly deeper than that of the sEVs group.

[0084] (2) Western blot and PCR detection of osteogenic protein expression levels: After 7 days of induction, the old culture medium was discarded, and the cell samples of each group were collected. The total protein was extracted and the protein concentration was determined. The expression levels of osteogenic-related proteins ALP (1:1000), OSX (1:1000), Runx2 (1:1000), and COL1 (1:1000) were detected by Western blot, and the expression levels of osteogenic genes were detected by PCR. The steps are as follows:

[0085] Extraction of total RNA from cells: Take samples from the 7th day of mineralization induction and extract total RNA according to the operating instructions of TaKaRa MiniBEST UniversalRNA Extraction Kit. The specific steps are as follows:

[0086] ① Aspirate and discard the old culture medium of each group of cells, wash the cells twice with PBS, discard the PBS, add 300 μL of pre-prepared Buffer RL (prepared according to the ratio of Buffer RL: 50×DTT Solution=50:1) to each well of the six-well plate, gently shake the plate to make the lysis solution evenly contact the cells, and place it horizontally for 20 min to fully lyse the cells. For cells that are firmly attached to the wall and difficult to fall off, use a cell scraper to peel them off;

[0087] ②Fully collect the cell lysate in each group of wells and transfer it to the gDNA-Eraser Spin Column. Centrifuge at 12000 rpm for 1 min, discard the gDNA-Eraser Spin Column, and retain the filtrate in the lower collection tube;

[0088] ③ Measure the volume of the filtrate and add an equal volume of 70% ethanol (prepared with RNase Free dH2O), mix thoroughly, transfer the mixture to the RNA Spin Column, centrifuge at 12000 rpm for 1 min, and discard the lower filtrate;

[0089] ④ Add 500 μL Buffer RWA to the upper column of RNA Spin Column, centrifuge at 12000 rpm for 30 seconds, and discard the lower filtrate;

[0090] ⑤ Add 600 μL Buffer RWB (with anhydrous ethanol pre-added) to the upper column of RNA Spin Column, centrifuge at 12000 rpm for 30 s, and discard the lower filtrate;

[0091] ⑥DNase I digestion:

[0092] A. Prepare a certain amount of DNase I reaction solution according to the following ratio based on the number of samples: 10×DNase I Buffer: Recombinant DNase I: RNase free dH2O = 5:4:41, and centrifuge briefly to mix the reaction solution;

[0093] B. Add 50 μL of DNase I reaction solution to the center of the membrane of the upper column of RNA Spin Column and let it stand at room temperature for 15 minutes;

[0094] C. Add 350 μL Buffer RWB to the upper column of RNA Spin Column, centrifuge at 12000 rpm for 30 s, and discard the lower filtrate;

[0095] ⑦Repeat step ⑤;

[0096] ⑧Reset the RNA Spin Column in the lower collection tube and centrifuge at 12000 rpm for 2 min to fully remove the residual liquid in the upper column;

[0097] ⑨Reset the RNA Spin Column in a new 1.5 mL RNase Free EP tube, add 50 μL RNase Free dH2O to the center of the upper column membrane, let stand at room temperature for 5 min, and centrifuge at 12000 rpm for 2 min to elute the RNA;

[0098] ⑩ After the extracted total RNA is thoroughly mixed, 2 μL is aspirated and its concentration is measured using a Quawell Q3000 micro-volume UV spectrophotometer.

[0099] Reverse transcription reaction: reverse transcription reaction was performed according to PrimeScript TM Follow the RT Master Mix (Perfect Real Time) manual. The specific steps are as follows:

[0100] ① Place the 0.2 mL RNase Free tube on an ice box and add each reagent according to the requirements in Table 6 to a total volume of 10 μL:

[0101] Table 6 PrimeScript TM Reverse transcription reaction

[0102]

[0103] ② Collect and mix the prepared mixture by instant centrifugation, and place it in a gradient PCR instrument for reverse transcription reaction. The reaction conditions are: 37°C for 15 min, 85°C for 5 s, and 4°C to terminate the reaction. The transcription reaction solution can be directly used in PCR experiments or temporarily stored at -80°C after dilution 10 times.

[0104] Real-time quantitative PCR: This experimental procedure is carried out according to the operating requirements of the TaKaRa kit. The specific steps are as follows:

[0105] ① Primer design: The primers required for this experiment ( ALP, OSX, Runx2, COL1, GAPDH ) The gene sequence is shown in Table 7;

[0106] Table 7 Primer sequences

[0107]

[0108] ② Prepare PCR reaction solution on ice according to the dosage of each component in Table 8:

[0109] Table 8 TB Green Premix Ex TaqII PCR reaction

[0110]

[0111] ③ After instant centrifugation, add the above reaction solution to a 96-well PCR reaction plate and centrifuge for 1 min to mix. TM The reaction was performed under the Real-Time PCR System according to the following program: Stage 1: 1 cycle, 95 °C for 30 s; Stage 2: 40 cycles, denaturation at 95 °C for 5 s, annealing and extension at 60 °C for 34 s;

[0112] ④After the PCR reaction, record the CT value of each gene and calculate the relative expression of the gene according to the formula x=2-∆∆Ct, where x is the CT value of each target gene. GAPDH Corrected fold relative to the control group.

[0113] WB and PCR results Figure 8 As shown in Figure CE, WB results show that sEVs can upregulate the expression level of osteogenic-related proteins in PDLSCs, and sEVs miR-423-5p The protein expression levels of Runx2 and COL1 were significantly upregulated (see Figure 8 C), and the gene levels of ALP and Runx2 (see Figure 8 Figure D), in which the gene level of COL1 was lower than that of the sEVs group, but still significantly higher than that of the control group (see Figure 8 Figure E), indicating that sEVs miR-423-5p It can enhance the upregulation effect of sEVs on bone markers in target cells.

[0114] (3) Alizarin red staining: After 10 days of induction, discard the old culture medium, wash the cells with PBS, aspirate the PBS and fix the cells with paraformaldehyde for 10 min, wash three times with PBS, add alizarin red staining solution to cover the cells, stain for 5 min in the dark, discard the staining solution, wash the floating color with PBS, and observe the formation of mineralized nodules in each group under wet conditions and take pictures.

[0115] Alizarin red staining results Figure 8 As shown in Figure B, the results showed that sEVs had no significant effect on the formation of PDLSCs mineralized nodules, while sEVs miR-423-5p It significantly promoted the formation of PDLSCs mineralized nodules, suggesting that sEVs miR-423-5p The osteogenic differentiation properties of sEVs were significantly enhanced.

[0116] The above results indicate that the engineered vesicles constructed by the method of the present invention significantly enhance the osteogenic properties of natural vesicles.

[0117] The positive and reverse strand nucleotide sequences and primer sequences of miR-423-5p in the present invention are as follows:

[0118] (1) Positive strand: UGAGGGGCAGAGAGCGAGACUUU. When preparing the nucleotide sequence table, replace "U" with "T" to prepare the nucleotide sequence table, specifically TGAGGGGCAGAGAGCGAGACTTT (SEQ ID NO. 1);

[0119] (2) Reverse strand: AAAGUCUCGCUCUCUGCCCCUCA. When preparing the nucleotide sequence table, replace "U" with "T" to prepare the nucleotide sequence table, specifically AAAGTCTCGCTCTCTGCCCCTCA (SEQ ID NO. 2).

[0120] (3) ALP : F: 5'-TAAGGACATCGCCTACCAGCTC-3' (SEQ ID NO.3); R: 5'-TCTTCCAGGTGTCAACGAGGT-3' (SEQ ID NO.4);

[0121] (4) OSX : F: 5'-AGGTGTATGGCAAGGCTTCG-3' (SEQ ID NO.5); R: 5'-GCAGGCAGGTGAACTTCTTCT-3' (SEQ ID NO.6);

[0122] (5) RUNX2 : F: 5'-CTTTACTTACACCCCGCCAGTC-3' (SEQ ID NO.7); R: 5'-AGAGATATGGAGTGCTGGTC-3' (SEQ ID NO.8);

[0123] (6) COL1 : F: 5'-AACATGGAGACTGGTGAGACCT-3' (SEQ ID NO.9); R: 5'-CGCCATACTCGAACTGGAATC-3' (SEQ ID NO.10);

[0124] (7) GAPDH : F: 5'-CTTTGGTATCGTGGAAGGACTC-3' (SEQ ID NO. 11); R: 5'-GTAGAGGCAGGGATGATGTTCT-3' (SEQ ID NO. 12).

Claims

1. A method for constructing a miR-423-5p high-abundance engineered vesicle, characterized in that: The miR-423-5p high-abundance engineered vesicles include small extracellular vesicles and miR-423-5p, the positive chain nucleotide sequence of the miR-423-5p is: UGAGGGGCAGAGAGCGAGACUUU, and the reverse chain nucleotide sequence is: AAAGUCUCGCUCUCUGCCCCUCA; The small extracellular vesicles are small extracellular vesicles secreted by dental follicle stem cells; The method for constructing the miR-423-5p high-abundance engineered vesicles comprises the following steps: (1) Mix miR-423-5p and nucleic acid transfection reagent, and then add small extracellular vesicles for incubation; (2) placing the product obtained in step (1) into an adsorption column and centrifuging to obtain miR-423-5p small extracellular vesicles; (3) Adding miR-423-5p small extracellular vesicles into an ultrafiltration tube for purification and concentration, retaining the upper liquid, and obtaining.

2. The method for constructing miR-423-5p high-abundance engineered vesicles according to claim 1, characterized in that: In step (1), the incubation temperature is 35-38°C and the incubation time is 0.5-2 h.

3. The method for constructing the miR-423-5p high-abundance engineered vesicle according to claim 1, characterized in that: In the step (2), the centrifugal speed is 1500-2500 rpm and the centrifugal time is 30-60 s.

4. The method for constructing miR-423-5p high-abundance engineered vesicles according to claim 1, characterized in that: The molecular weight cut-off of the ultrafiltration tube in step (3) is 25-35 kD.